CMS Gene Therapy Access Model Expansion: What Genetic Testing Labs Should Know
Short answer: Not directly. CMS announced on October 27, 2026 that it will broaden its Cell and Gene Therapy Access Model beyond sickle cell disease, but the CMS announcement does not mention diagnostics or testing requirements. Labs should treat it as an early signal: more gene-therapy-eligible conditions may mean more demand for well-documented confirmatory genetic testing.
What CMS actually announced
On October 27, 2026, the CMS Innovation Center published an update on its Cell and Gene Therapy (CGT) Access Model. The model is voluntary. CMS negotiates outcomes-based agreements with manufacturers on behalf of state Medicaid programs, rather than leaving each state to negotiate alone. Until now the model has covered sickle cell disease therapies.
According to CMS, initial evaluation results indicated that CMS-led negotiation eased administrative burden for states, and the model has shown strong state buy-in. On that basis, CMS plans to broaden the model beyond sickle cell disease and invite manufacturers of other cell and gene therapies to apply. CMS says a Request for Applications will be released in the coming months, and that it aims to begin negotiations sooner after FDA approval and to accept applications for therapies that are already approved or licensed.
Trade coverage framed the direction more specifically: a Pink Sheet headline says the model will expand to rare disease and some cancers. The body of that article was not available to us, so treat the exact conditions as unconfirmed until the RFA is published.
What the announcement does not say
This matters for a B2B audience, so it is worth being blunt. The CMS page does not name specific therapies, does not give a participating-state roster, does not publish dollar figures, and does not mention genetic testing or diagnostic laboratories. Nothing in it creates a new lab coverage rule, a new billing code, or a new documentation mandate.
That means any claim that this model changes lab reimbursement today would be speculation. What can be said is narrower: the model sits on the Medicaid drug side, and laboratories sit upstream of it, producing the diagnostic evidence that a payer reads when deciding whether a patient qualifies for an expensive one-time therapy.
Why labs should still pay attention
Gene therapies are, by design, tied to a molecular diagnosis. Whenever a therapy is approved for a defined genetic condition, the clinical and payer workflow downstream usually asks the same question: is the genotype confirmed, and is the report clear enough to rely on? The CMS announcement does not say this, but it is the logical consequence of how targeted therapies are reviewed, and it is where laboratories feel the effect first.
Three practical pressure points follow for molecular labs, medical directors, and genetic counselors.
Report clarity. A prior authorization reviewer at a state Medicaid program is rarely a molecular geneticist. Reports that state the gene, the variant in HGVS nomenclature, the classification, and the clinical interpretation in plain, separable fields are easier to match to a payer checklist than narrative-only reports.
Classification stability. A variant of uncertain significance is not the same as a confirmed pathogenic result, and reclassification over time can change eligibility. Our guide on VUS reclassification and recontact covers the lab responsibilities that follow.
Claims hygiene. Testing that precedes a therapy request still has to survive ordinary claim review. Order documentation, diagnosis coding, and medical necessity are the usual failure points, as we describe in why genetic testing claims get denied and ICD-10 codes for genetic testing.
The FDA side of the same announcement
CMS did not act alone. Per the joint HHS announcement, FDA issued draft guidance titled "Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management." It introduces an Individualized Feature Space, a set of predefined boundaries within which a genome editing product can vary from patient to patient while remaining under a single Biologics License Application.
Under the draft, new patient-specific variants that fall within the Individualized Feature Space and show adequate safety and activity in assays could be added to the BLA without new clinical trials, relying on existing trial data plus laboratory in vitro data for each new variant. The draft also addresses safety testing, including risks of unintended genetic changes. Comments are being accepted on docket FDA-2026-D-11783 within 30 days of Federal Register publication. We discuss the laboratory angle in our FDA guidance analysis.
Whether any of this creates demand for commercial laboratory services is not stated by either agency. It is a reasonable area to monitor, not a forecast.
A readiness checklist for the next two quarters
None of the following is required by CMS. It is a low-cost way to be ready if the RFA brings new genetic conditions into scope.
First, audit how your reports present genotype. Make sure the gene, transcript, variant, zygosity, and classification appear in structured fields. Second, confirm your reflex and confirmatory testing policies are written down, so an ordering clinician can see what you will and will not do. Third, review your turnaround-time commitments, since faster post-approval negotiation could compress the window in which families and providers expect results. Fourth, watch the Federal Register and CMS Innovation Center pages for the RFA, then read the eligibility language for any reference to diagnostic confirmation.
Finally, keep your compliance posture steady. CMS is simultaneously pursuing anti-fraud rulemaking that has singled out genetic and molecular testing, so documentation discipline is worth more now than it was a year ago. See our overview of national MolDX expansion for that context, and the ScreenMyGene homepage for how our platform supports clinical decision-making and documentation.
Frequently asked questions
Does the CGT Access Model change how Medicare pays for genetic tests?
No. CMS describes the model as a voluntary arrangement in which it negotiates outcomes-based agreements with manufacturers on behalf of state Medicaid programs. The announcement does not mention diagnostics, the Clinical Laboratory Fee Schedule, or any change to laboratory coverage or payment.
Which conditions will the expanded model cover?
CMS has not said. Its announcement refers to other cell and gene therapies without naming them. A Pink Sheet headline reports expansion to rare disease and some cancers, but the specifics should wait for the Request for Applications, which CMS says will be released in the coming months.
When will the Request for Applications be released?
CMS says "in the coming months" and has not given a date. It also says it will accept applications for therapies already approved or licensed, and aims to begin negotiations sooner after FDA approval. Monitor CMS Innovation Center announcements for the actual release.
What should a molecular lab do now?
Nothing is mandated. Prudent steps include making variant, classification, and zygosity fields easy to read, documenting confirmatory testing policies, and tightening order and diagnosis documentation so claims survive review. Then watch for the RFA and read any language about diagnostic confirmation.
How does the FDA draft guidance relate?
It was announced alongside the CMS update. The draft describes how individualized genome editing products could add patient-specific variants to one BLA using laboratory data. It is about product approval, not laboratory billing, though it highlights growing reliance on assay data.
This article is educational decision support for laboratories and clinicians, not legal, coding, or medical advice. Policies change; verify against current CMS, FDA, and payer documents before acting.
Sources: CMS Innovation Center, "Innovation Insight: CGT Access Model Builds on Initial Success with New Therapies to Be Added Following Manufacturer Negotiations" (Oct 27, 2026); HHS/FDA/CMS joint announcement, "FDA and CMS Announce New Steps to Advance Gene Therapies and Expand Access for Patients with Rare Diseases" (Oct 27, 2026); Citeline Pink Sheet headline on Medicaid CGT model expansion; FDA docket FDA-2026-D-11783.